香港股市 將收市,收市時間:5 小時 33 分鐘

Krystal Biotech, Inc. (KRYS)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
177.78-4.94 (-2.70%)
收市:04:00PM EDT
172.30 -5.48 (-3.08%)
收市後: 04:56PM EDT

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com

版塊Healthcare
行業Biotechnology
全職員工229

高階主管

名稱頭銜支付行使價出生年份
Mr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President & CEO1.32M1965
Ms. Suma M. KrishnanFounder, President of R&D and Director895.33k1965
Ms. Kathryn A. RomanoExecutive VP & Chief Accounting Officer614.87k2.35M1982
Mr. John ThomasGeneral Counsel & Corporate Secretary
Mr. John KarakkalVice President of North American Sales & Marketing
Ms. Christine WilsonHead of U.S. Sales and Marketing
Dr. Stephane Paquette Ph.D.Vice President of Corporate Development
Mr. Josh SuskinDirector of Human Resources & Operations
Mr. Laurent GouxSenior VP & GM of Europe
Mr. David ChienSenior Vice President of Clinical Development
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

公司管治

截至 2024年6月1日 止,Krystal Biotech, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:3;董事會:9;股東權利:8;現金賠償:5。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。